Valeant's Brodalumab Faces Conflicting FDA Views On Suicide Risk

Advisory committee will hear agency reviewers' different conclusions on plaque psoriasis drug's approvability due to potential psychiatric effects and whether a REMS can help mitigate the risks.

FDA’s Dermatologic and Ophthalmic Drugs Advisory Committee will convene July 19 to mediate separate conclusions reached by three different agency divisions regarding the safety of Valeant Pharmaceuticals International Inc.’s plaque psoriasis candidate Siliq (brodalumab).

The suicides of six clinical trial subjects taking the drug, along with 40 brodalumab-treated patients who exhibited suicidal ideation and...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers